MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Seres Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$2.42−0.04 (-1.63%)

Close on Oct 19, 2026

Market cap: $23.59M
P/E (TTM): –
Dividend yield: –

Seres Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	0.79	0	0	7.13	145	33	35	28	32	22	0	–	–
Research & Development	49	65	118	110	142	91	80	96	89	82	38	11	4.81
General & Administrative	39	53	78	70	69	31	25	33	34	33	17	4.36	1.25
Operating Expenses	95	121	195	180	209	121	106	129	123	115	55	15	6.05
Operating Income	-94	-121	-195	-180	-64	-88	-72	-100	-91	-93	-55	-15	-6.05
Interest Expense	0	0	2.47	6.02	2.91	2.92	0.50	–	–	–	–	–	–
Interest & Investment Income	2.23	3.97	7.30	3.06	2.87	0.95	1.03	1.17	1.59	2.23	0.64	–	–
Other Non-Operating Income	100	-4.46	4.97	-3.67	-1.09	-1.00	1.60	1.34	2.02	1.26	0.08	-1.63	-0.05
Merger & Restructuring Charges	1.03	–	5.61	–	0	0	1.49	0	0	–	–	–	–
Asset Impairment Charges	–	–	0	0	0	0	0	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	0.19	-0.32	0	0	–	–	-0.10	–	–	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	0	0
Income from Continuing Operations	5.70	-126	-190	-184	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	0	126	76	-67	–	–	–	–	–	–	–	–	–
Net Income	5.70	0.14	-114	-250	-66	-89	-70	-99	-89	-92	-55	-17	-6.10
Net Income to Common	5.70	0.14	-114	-250	-66	-89	-70	-99	-89	-92	-55	-18	-6.98
EPS (Basic)(per share)	0.64	0.00	-17.77	-46.20	-14.40	-22.40	-24.80	-48.60	-44.20	-46.00	-46.60	-53.40	-21.80
EPS (Diluted)(per share)	0.64	0.00	-17.77	-46.20	-14.40	-22.40	-24.80	-48.60	-44.20	-46.00	-46.60	-53.40	-21.80
Shares Outstanding (Basic, Weighted)(shares)	8.86	7.77	6.40	5.40	4.59	3.99	2.83	2.04	2.02	1.99	1.18	0.34	0.32
Shares Outstanding (Diluted, Weighted)(shares)	8.87	7.77	6.40	5.40	4.59	3.99	2.83	2.04	2.02	1.99	1.18	0.34	0.32
EBITDA	-90	-116	-189	-173	-59	-82	-64	-92	-84	-89	-54	-15	-5.96
Net Interest Income	–	–	–	–	–	–	–	–	1.59	1.26	0.08	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -4462.8%
Net margin: -1192.9%
Return on equity, FY2025: 19.6%

Financial strength

Current ratio: 2.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 77.8%

Valuation

P/E ratio: –
Price to sales: 12.53
Price to book: 0.68
Dividend yield: –